Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP11A1 | P05108 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21848668 | 1.00 | CRBN (0.41) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| SCHEMBL8259939 | 1.00 | CRBN (0.41) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Bromide SCHEMBL283262 | 0.98 | CRBN (0.40) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Bromide SCHEMBL283607 | 0.98 | CRBN (0.40) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Hydrochloric Acid SCHEMBL18449191 | 0.98 | CRBN (0.40) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Bromide SCHEMBL283263 | 0.98 | CRBN (0.40) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Hydrochloric Acid SCHEMBL1398914 | 0.98 | CRBN (0.40) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Hydrochloric Acid SCHEMBL18449275 | 0.98 | CRBN (0.40) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Hydrochloric Acid SCHEMBL3543099 | 0.96 | CRBN (0.39) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Bromide SCHEMBL1403663 | 0.96 | CRBN (0.39) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697990-B | Indazole-based compounds and related methods of use | 阿维纳斯企业公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4565585-A1 | COMPOUNDS FOR MODULATING RET PROTEIN | Bristol-Myers Squibb Company (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-04-10 | — | — | US | disclosed |
| CN-118852145-A | GSPT1 degradation agent and application thereof | 南京圣和药业股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-12053469-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| WO-2024030968-A1 | COMPOUNDS FOR MODULATING RET PROTEIN | BRYSTOL-MYERS SQUIBB COMPANY (US) | 2024-02-08 | — | — | WO | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-12-05 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20030144325-A1 | Isoindolines, method of use, and pharmaceutical compositions | MULLER GEORGE W (US) | 2003-07-31 | — | — | US | disclosed |
| US-6555554-B2 | 2,6-dioxopiperidin; antiinflammatory agent; reduces tumor necrosis factor alpha levels and/or increases cAMP | CELGENE CORPORATION | 2003-04-29 | — | — | US | disclosed |
| EP-1285916-A1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF alpha levels | CELGENE CORPORATION (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-0925294-B1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORP (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020183360-A1 | Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels | MULLER GEORGE W (US) | 2002-12-05 | — | — | US | disclosed |
| US-6476052-B1 | Isoindolines, method of use, and pharmaceutical compositions | CELGENE CORPORATION | 2002-11-05 | — | — | US | disclosed |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | MULLER GEORGE W (US) | 2002-04-18 | — | — | US | disclosed |
| US-6335349-B1 | AGENTS THAT REDUCE LEVELS OF TUMOR NECROSIS FACTOR; ANTICARCINOGENIC AND ANTIINFLAMMATORY AGENTS; TREATMENT OF AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2002-01-01 | — | — | US | disclosed |
| US-6316471-B1 | TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2001-11-13 | — | — | US | disclosed |
| US-6281230-B1 | TREATING INFLAMMATION, INFLAMMATORY DISEASE OR AUTOIMMUNE DISEASE IN A MAMMAL | CELGENE CORPORATION | 2001-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | CRBN 2/4885CYP19A1 4440/4885CYP3A4 3655/4885 |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CRBN 3/4885CYP19A1 43/4885CYP3A4 2249/4885 |
| US-12053469-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, MDM2 | CRBN 2/4885CYP19A1 4440/4885CYP3A4 3655/4885 |
| US-20030144325-A1 | Isoindolines, method of use, and pharmaceutical compositions | TNF, INA, VIP | CRBN 4462/4885CYP19A1 811/4885CYP3A4 365/4885 |
| US-20020183360-A1 | Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels | TNF, TNFRSF1A, TRAF2 | CRBN 3437/4885CYP19A1 1343/4885CYP3A4 1816/4885 |
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | RXFP3, RXFP1, NPY2R | CRBN 3123/4885CYP19A1 2192/4885CYP3A4 1116/4885 |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | TNF, OPRK1, OPRD1 | CRBN 4469/4885CYP19A1 452/4885CYP3A4 182/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | CRBN 1/4885CYP19A1 3418/4885CYP3A4 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.